Apolipoprotein D Expression Dynamics During Cuprizone-Induced Demyelination and Remyelination in a Mouse Model of Multiple Sclerosis
Authors:
Open Access
- 6 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8692
Abstract
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) characterized by oligodendrocyte (OLG) degeneration, myelin loss, and impaired remyelination. Apolipoprotein D (Apo D), a glia-derived lipocalin, has emerged in recent decades as a neuroprotective molecule involved in lipid transport, oxidative stress regulation, and inflammation control during aging and neurodegenerative diseases like MS. However, its role in demyelination/remyelination dynamics remains poorly defined. In this study, we used the cuprizone (CPZ)-induced demyelination model in C57BL/6 mice to analyze Apo D expression patterns in the corpus callosum during de- and remyelination. We also assessed whether the atypical antipsychotic clozapine (CLO), previously shown to upregulate Apo D in vivo, could modulate its expression and influence myelin recovery in this pathological context. Using a combination of magnetic resonance imaging, Luxol fast blue staining, and double immunohistochemistry, we demonstrated that CPZ treatment for 3 or 6 weeks led to significant demyelination, hydrocephalus, and reduced motor cortex thickness, which were partially reversed after treatment cessation. Apo D expression in OLGs was significantly reduced by CPZ exposure, both at the protein level and in terms of immunoreactive cell counts, but was restored following treatment withdrawal. Notably, co-administration of CLO prevented the CPZ-induced reduction in Apo D expression in OLGs, although it did not attenuate myelin loss. In this way, our results reveal a strong correlation between Apo D expression and OLG/myelin integrity in vivo. While CLO did not exert remyelinating effects, it preserved Apo D levels under demyelinating conditions, suggesting a potential indirect neuroprotective mechanism. These findings support the relevance of Apo D in CNS myelin homeostasis and highlight its potential as a molecular target for therapeutic intervention in demyelinating diseases such as MS.Keywords
Funding Information
- Fondo de Investigaciones Sanitarias (FIS) (PI15/00601)
- European Regional Development Fund and European Social Fund “Investing in your future” (PI15/00601)
This publication has 140 references indexed in Scilit:
- Cuprizone feeding induces swollen astrocyte endfeetPflügers Archiv - European Journal of Physiology, 2022
- Biological models in multiple sclerosisJournal of Neuroscience Research, 2019
- The Spatial and Temporal Characters of Demyelination and Remyelination in the Cuprizone Animal ModelThe Anatomical Record, 2019
- Myelin extracellular leaflet compaction requires apolipoprotein D membrane management to optimize lysosomal‐dependent recycling and glycocalyx removalGlia, 2017
- The translational biology of remyelination: Past, present, and futureGlia, 2014
- Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizoneEuropean Archives of Psychiatry and Clinical Neuroscience, 2013
- ApoD, a glia‐derived apolipoprotein, is required for peripheral nerve functional integrity and a timely response to injuryGlia, 2010
- The cuprizone animal model: new insights into an old storyActa Neuropathologica, 2009
- Regeneration‐associated high level expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve.The EMBO Journal, 1990
- AN ENCEPHALOGRAPHIC RATIO FOR ESTIMATING VENTRICULAR ENLARGEMENT AND CEREBRAL ATROPHYArchives of Neurology And Psychiatry, 1942